# A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

> **NCT04543695** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 255 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **COMBINATION_PRODUCT:** Concurrent Chemoradiotherapy
- **DRUG:** XELOX
- **DRUG:** mFOLFOX
- **PROCEDURE:** TME

## Key facts

- **NCT ID:** NCT04543695
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-15
- **Primary completion:** 2022-07-12
- **Final completion:** 2025-06-01
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543695, "A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04543695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*